Login to Your Account



Clinic Roundup


Friday, April 5, 2013
Merrimack Pharmaceuticals Inc., of Cambridge, Mass., said one cohort of a Phase II non-small-cell lung cancer (NSCLC) study did not meet its primary endpoint. The cohort evaluated MM-121 in combination with Tarceva (erlotinib, Astellas Pharma Inc.) to treat patients with NSCLC whose disease progressed on an anti-EGFR tyrosine kinase inhibitor (EGFR-TKI).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription